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physicians $3.2 billion (95% CI: $2.88–$3.49 billion) in 2006.
CONCLUSION: Medicaid PDLs for statins and antihyperten-
sives have generated considerable costs for physicians. Physicians
would incur substantial additional costs if Medicare adopted
similarly-structured PDLs for Part D.
PODIUM SESSION I: WOMEN’S HEALTH
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OBJECTIVES: To determine the predictors of breast cancer
patients’ (BCPs) willingness to accept local and systemic therapy.
METHODS: Cross-sectional survey of BCPs ages 36–80 at the
University of Maryland Greenebaum Cancer Center, Baltimore,
MD. Since “treatment” is considered a “short-term” health state,
the chained procedure for the time trade-off (TTO) was used to
assess TTO. Willingness to accept therapy was determined using
“minimum cancer-free years to accept therapy” (CFYs) as the
dependent variable. The number of CFYs was calculated based
upon BCPs TTO responses for mastectomy (MRM), breast-con-
serving therapy (BCT), chemotherapy (CTX) and tamoxifen
(TAM). Demographic and clinical data were abstracted from
medical records. Tobit regression models were used for multi-
variate analyses. RESULTS: Mean age = 56.0 years (SD ± 9.43,
n = 77); 58.2% were white; 75.6% had early stage cancer. BCPs
required more CFYs (median = 4) to accept MRM than to accept
BCT, CTX, or TAM (median 1 year for each). For all forms of
therapy, the mode = 0, suggesting that BCPs were willing to
accept therapy even if it provided no additional CFYs. Late stage
patients required more CFYs to accept TAM (β = 6.61, p =
0.0489); similarly late stage patients in good physical health
required more CFYs to have MRM (β = 0.50, p = 0.0322). Treat-
ment-experienced BCPs were more willing to accept that type of
therapy than those who were treatment-naïve. Younger patients
(<65) required fewer CFYs to accept chemotherapy (age group
50–54, β = −4.77, p = 0.0403; 55–59, β = −7.25, p = 0.0019).
Being non-white and having less education were associated with
requiring fewer CFYs to accept to accept CTX (β = −3.86, p =
0.0087; β = −5.10, p = 0.0193, respectively). CONCLUSION:
BCPs required relatively few CFYs to accept treatment. Willing-
ness-to-accept fewer CFYs for CTX among those with less edu-
cation and of younger age is consistent with treatment patterns
previously-published. The fact that non-whites (primarily
African Americans) required fewer CFYs to accept CTX appears
in contrast to observed underutilization of CTX among African
American BCPs.
WH2
STANDARD GAMBLE TECHNIQUES FOR THE MEASUREMENT
OF TREATMENT RELATED TOXICITY IN ONCOLOGY:
APPLICATION TO BREAST CANCER
Simons WR
Global Health Economics & Outcomes Research, Inc, Summit, NJ,
USA
OBJECTIVES: To assess women’s preferences/utilities for health
states speciﬁc to advanced stage breast cancer including baseline
diagnoses of advanced stage breast cancer (ABC), treatment
response, no treatment response, disease progression and espe-
cially their point of indifference between treatment-related toxi-
cities and treatment response. METHODS: FACT-B QOL data
from patients with ABC were used to compose health narratives
consisting of physical, social, emotional, functional well-being,
additional concerns content domains. Toxicities were described
separately. 100 peri/post menopausal women were interviewed
by a woman using Visual Analogue (VA) standard gamble tech-
niques (SG). Baseline ABC, treatment response, no treatment
response and disease progression were conducted using SG as
usual with oscillating risks of perfect health (1) and immediate
death (0) as anchors OR the HS narrative with 100% certainty.
For toxicity, however, the true trade-off is treatment response
with an associated risk of toxicity OR no treatment and remain-
ing with 100% certainty at baseline ABC. This allows one to
measure how much chance of response a woman needs to be
indifferent to the corresponding chance of toxicity. RESULTS:
Mean age was 55.76, 64% were postmenopausal, 11% had
breast cancer while 16% had another type of cancer previously.
VAS scores were 51.8 (p < 0.01) for baseline ABC, 82.5 (p <
0.01) for response, 57.5 (p < 0.01) for no response and 38.4 (p
< 0.01) for disease progression. SG regression results were 0.64
(p < 0.01) for baseline, 0.76 (p < 0.01) for treatment response,
0.67 (p < 0.01) for no response, and 0.50 (p < 0.01) for disease
progression. The trade-off between a chance of response with a
corresponding chance of toxicity yielded a value of 0.34 (p <
0.01) or utility score of 0.66 (p < 0.01). CONCLUSION: Women
need at least a 34% chance of treatment response to be indif-
ferent to treatment-related toxicity. These measured values are
more appropriate for Quality-adjusted Time Without Symptoms
of disease and Toxicity (Q-TWiST) analysis to value oncology
treatment.
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OBJECTIVES: To determine whether vasomotor symptom
reduction is associated with improved work productivity using
pooled data from 2 clinical trials for the relief of menopausal hot
ﬂushes with desvenlafaxine succinate (DVS). METHODS: A
total of 843 postmenopausal women experiencing 50 or more
moderate-to-severe hot ﬂushes per week received 100 or 150 mg/
day DVS or placebo in 2 randomized, double-blind, placebo-
controlled trials. Subjects kept daily hot ﬂush and sleep diaries
and completed the Proﬁle of Mood States (POMS) and Work
Limitations Questionnaire (WLQ) at baseline and week 12. To
control for multiplicity, the data were analyzed using multivari-
ate analysis of covariance (MANCOVA), adjusting for age, race,
type of menopause, and baseline values. RESULTS: At both 100-
and 150-mg doses, DVS reduced the number and severity of hot
ﬂushes from baseline to week 12 compared with placebo (all
comparisons, P < 0.0001). DVS reduced the number of night-
time awakenings due to hot ﬂushes (P < 0.0001) and improved
self-perceived sleep quality (P < 0.05) at both doses compared
with placebo. The 100 mg dose also signiﬁcantly increased the
daily number of minutes slept (P < 0.05). POMS total mood dis-
turbance score improved signiﬁcantly in both DVS dose groups
compared with placebo (P < 0.001). Work limitation, measured
by WLQ total index score, decreased signiﬁcantly from baseline
to week 12 in subjects treated with 100 mg DVS (adjusted mean
[SE] reduction = −3.3 [0.9]; P = 0.0115) compared with placebo
(−1.4 [0.9]). The 100 -mg dose group had signiﬁcant improve-
ment on the time management (P = 0.0354), mental-interper-
